Fosdenopterin Hydrobromide Patent Expiration

Fosdenopterin Hydrobromide is Used for treating Molybdenum Cofactor Deficiency Type A. It was first introduced by Sentynl Therapeutics Inc in its drug Nulibry on Feb 26, 2021.

Fosdenopterin Hydrobromide Patents

Given below is the list of patents protecting Fosdenopterin Hydrobromide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Nulibry US7504095 Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency Jan 31, 2025 Sentynl Theraps Inc

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳